Back to Browse Journals » ChronoPhysiology and Therapy » Volume 1

Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time

Authors Sumit Patil, Swati Pund, Amita Joshi, et al

Published Date February 2011 Volume 2011:1 Pages 1—10

DOI http://dx.doi.org/10.2147/CPT.S16504

Published 21 February 2011

Sumit Patil1, Swati Pund2, Amita Joshi2, Chamanlal J Shishoo2, Aliasgar Shahiwala1
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India; 2Department of Pharmaceutics, BV Patel PERD Centre, Ahmedabad, India

Background: The objective of this study was to develop and evaluate a press-coated pulsatile drug delivery system intended for treatment of early morning stiffness and symptomatic relief from pain in patients with rheumatoid arthritis.
Methods: The formulation involved press coating of a rupturable coat around a rapidly disintegrating core tablet of aceclofenac. A three-factor, two-level, full factorial design was used to investigate the influence of amount of glyceryl behenate, amount of sodium chloride in the coating composition, and the coating level on the responses, ie, lag time to release and amount of aceclofenac released in 450 minutes.
Results: Glyceryl behenate and the coating level had a significant influence on lag time, while sodium chloride helped in the rupture of the coat by acting as a channeling agent. After the coat was ruptured, the core tablet showed a rapid release of aceclofenac due to the presence of Ac-Di-Sol®. Graphical analysis of effects by Lenth's method and Bayesian analysis of coefficients enabled identification of variables active on the selected responses. The optimized formulation comprised 20% w/w glyceryl behenate and 2.2% w/w sodium chloride with a 650 mg coating level, and showed a desired lag time of 358.23 minutes, which mimics the fluctuating symptoms of rheumatoid arthritis, followed by rapid release of aceclofenac.

Keywords: chronotherapy, pulsatile delivery, rupturable coat, aceclofenac
 

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads

Schroyen S, Adam S, Jerusalem G, Missotten P

Clinical Interventions in Aging 2015, 10:117-125

Published Date: 31 December 2014

Endothelial keratoplasty with infant donor tissue

Kobayashi A, Yokogawa H, Yamazaki N, Masaki T, Sugiyama K

Clinical Ophthalmology 2014, 8:1827-1830

Published Date: 11 September 2014

Antibacterial properties of silver nanoparticles synthesized using Pulicaria glutinosa plant extract as a green bioreductant

Khan M, Khan ST, Khan M, Adil SF, Musarrat J, Al-Khedhairy AA, Al-Warthan A, Siddiqui MRH, Alkhathlan HZ

International Journal of Nanomedicine 2014, 9:3551-3565

Published Date: 28 July 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Epidemiology of nonfatal stroke and transient ischemic attack in Al-Kharga District, New Valley, Egypt

Farghaly WM, El-Tallawy HN, Shehata GA, Rageh TA, Abdel-Hakeem NM, Elhamed MA, Al-Fawal BM, Badry R

Neuropsychiatric Disease and Treatment 2013, 9:1785-1790

Published Date: 18 November 2013

Current status of NADPH oxidase research in cardiovascular pharmacology

Rodiño-Janeiro BK, Paradela-Dobarro B, Castiñeiras-Landeira MI, Raposeiras-Roubín S, González-Juanatey JR, Álvarez E

Vascular Health and Risk Management 2013, 9:401-428

Published Date: 25 July 2013

Optimal treatment of actinic keratoses

Uhlenhake EE

Clinical Interventions in Aging 2013, 8:29-35

Published Date: 14 January 2013

Corrigendum

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM

Drug Design, Development and Therapy 2011, 5:487-488

Published Date: 28 November 2011